ACXP
Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc
$ACXP Reports Q4 2022 and Full-Year Financial Results
Acurx Pharmaceuticals, a biopharmaceutical company released its Q4 and full-year 2022 results. The company ended the year with $9.1mn cash on hand with an increase in losses, primarily due to Phase 2b trial-related costs. The CEO and CFO will conduct a conference call to provide a business update. Acurx is currently enrolling Phase 2b clinical trial patients for CDI, with ibezapolstat showing complete eradication of C. difficile by day three of the treatment. Although cash on hand has decreased, Acurx's R&D goals and business objectives remain grounded with a considerable market size of C. difficile infections in the US.
5d ago
$ACXP